Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    21282551 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Condition: Metastatic Cancers Other Than Melanoma That Express ESO Antigen
Interventions: Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin
2 Recruiting T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Conditions: Metastatic Cancer;   Metastatic Melanoma
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR
3 Recruiting T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Condition: Metastatic Cancer That Express the MAGE-A3-DP4 Antigen
Interventions: Biological: Anti-MAGE-A3-DP4 TCR;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin

Indicates status has not been verified in more than two years